Glycoprotein biomarkers for esophageal adenocarcinoma and Barrett's esophagus and uses thereof
AssigneeThe Council of the Queensland Institute of Medical Research
InventorsMichelle Mei Chih Hill, Alok Shah, Kim-Ahn Lê Cao
Life of this patent
Estimating the term…
Abstract
Disclosed are biomarkers for Barrett's esophagus and esophageal adenocarcinoma, and uses thereof, such as in methods for detecting the presence, and monitoring progression, of Barrett's esophagus and esophageal adenocarcinoma. Also disclosed are methods for treating and methods of monitoring the treatment of Barrett's esophagus and esophageal adenocarcinoma, as well as kits and compositions for use in such methods.
Claims15
A method for treating a subject who has esophageal adenocarcinoma (EAC) or Barrett's esophagus (BE), the method comprising:
- (a) contacting a sample from the subject with a glycan-binding molecule specific for at least one glycospecies of at least one glycoprotein under conditions that permit binding of the glycan-binding molecule to the at least one glycospecies, wherein the glycan-binding molecule comprises jacalin (JAC) and the at least one glycoprotein comprises alpha-1-antitrypsin;
- (b) determining a level of the at least one glycospecies of the at least one glycoprotein bound to the glycan binding molecule, wherein the at least one glycospecies is differentially expressed between EAC and BE;
- (c) determining the subject as having EAC or BE based on whether the level of the at least one glycospecies of the at least one glycoprotein bound to the glycan binding molecule a predetermined threshold that correlates with EAC or BE;
- and
- (d)(1) where the subject is determined to have EAC, administering to the subject a treatment selected from the group consisting of:
- esophagectomy, chemotherapy, immunotherapy, and radiation therapy;
- and (2) where the subject is determined to have BE, administering to the subject a treatment selected from the group consisting of:
- a diet and exercise regimen, a therapeutic agent to reduce acid reflux, photodynamic therapy (PDT), and endoscopic mucosal resection (EMR).
A method for treating a subject who has esophageal adenocarcinoma (EAC) or Barrett's esophagus (BE), the method comprising:
- (a) contacting a sample from the subject with jacalin (JAC) to bind any alpha-1-antirypsin present in the sample;
- (b) determining the level of alpha-1-antirypsin from the amount bound by JAC;
- (c) determining the subject as having EAC where the level of alpha-1-antirypsin is characteristic of EAC and identifying the subject as having BE where the level of alpha-1-antirypsin is characteristic of BE;
- and
- (d)(1) where the subject is determined to have EAC, administering to the subject a treatment selected from the group consisting of:
- esophagectomy, chemotherapy, immunotherapy, and radiation therapy;
- and (2) where the subject is determined to have BE, administering to the subject a treatment selected from the group consisting of:
- a diet and exercise regimen, a therapeutic agent to reduce acid reflux, photodynamic therapy (PDT), and endoscopic mucosal resection (EMR).
Dependencies are inferred from the claim text.